Volume 145, Issue 5, Pages 978-986.e5 (November 2013) Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC  Marc Ferrante, Jean–Frederic Colombel, William J. Sandborn, Walter Reinisch, Gerassimos J. Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert R. D'Haens, Christien J. van der Woude, Silvio Danese, Robert H. Diamond, Alessandra Faria Oortwijn, Kezhen L. Tang, Michael Miller, Freddy Cornillie, Paul J. Rutgeerts  Gastroenterology  Volume 145, Issue 5, Pages 978-986.e5 (November 2013) DOI: 10.1053/j.gastro.2013.08.010 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Flow chart of patient selection. For the present subgroup analysis of the SONIC trial, only patients who had evaluable endoscopic lesions at baseline, who underwent repeat endoscopy at week 26, and who had CDAI and CRP concentrations assessed both at baseline and week 26 were included. Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Predictive value of mucosal healing, endoscopic response, and segmental mucosal healing at week 26 for corticosteroid-free clinical remission at week 50 (n = 172). The first bar represents the sensitivity (95% CI), and the second bar represents the specificity (95% CI). CFREM, corticosteroid-free clinical remission (based on a decrease from baseline in CDEIS score of at least 50%); ER SES-CD, endoscopic response based on the Crohn's disease endoscopic index of severity (a decrease from baseline in CDEIS of at least 50%); ER SES-CD, endoscopic response based on the simple endoscopic score for Crohn's disease (a decrease from baseline in SES-CD of at least 50%); MH, mucosal healing, absence of mucosal ulcerations; Sens, sensitivity; SMH, segmental mucosal healing, a disappearance of mucosal ulcerations in at least one of the evaluated segments; Spec, specificity. Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 ROC curves for corticosteroid-free clinical remission at week 50 evaluating a relative change in (A) SES-CD and (B) CDEIS from baseline to week 26 (n = 172). Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 1 SES-CD. Endoscopic findings for this example include ulcerated stenosis of the ileocecal valve, 12% of the right colon is estimated to be involved, 8% of the right colon is estimated to be ulcerated, all other colon segments look normal, and the terminal ileum cannot be evaluated. Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 2 CDEIS. Endoscopic findings for this example include ulcerated stenosis of the ileocecal valve, 12% of the right colon is estimated to be involved, 8% of the right colon is estimated to be ulcerated, all other colon segments look normal, and the terminal ileum cannot be evaluated. Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 3 Predictive value of mucosal healing, endoscopic response, and segmental mucosal healing at week 26 for (A) clinical remission, (B) endoscopic response Δ100 points, and (C) endoscopic response Δ70 points at week 50 (N = 172). The first bar represents the sensitivity (95% CI), and the second bar represents the specificity (95% CI). ER CDEIS, endoscopic response based on a decrease from baseline in CDEIS score of at least 50%; ER SES-CD, endoscopic response based on a decrease from baseline in SES-CD of at least 50%; MH, mucosal healing, absence of mucosal ulcerations; REM, clinical remission (decrease to CDAI <150 points); RESΔ100, clinical response with a reduction in CDAI with ≥100 points or decrease to CDAI <150 points; RESΔ70, clinical response with a reduction in CDAI with ≥70 points or decrease to CDAI <150 points; Sens, sensitivity; SMH, segmental mucosal healing, a disappearance of mucosal ulcerations in at least one of the evaluated segments; Spec, specificity. Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 4 ROC curves for the prediction of CFREM at week 50 evaluating values of (A) SES-CD or (B) CDEIS at week 26 and absolute change in (C) SES-CD or (D) CDEIS scores from baseline to week 26 (N = 172). Gastroenterology 2013 145, 978-986.e5DOI: (10.1053/j.gastro.2013.08.010) Copyright © 2013 AGA Institute Terms and Conditions